1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 48 pages

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015’, provides an overview of the Female Hypoactive Sexual Desire Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Female Hypoactive Sexual Desire Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Overview 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Comparative Analysis 8
Female Hypoactive Sexual Desire Disorder - Therapeutics under Development by Companies 9
Female Hypoactive Sexual Desire Disorder - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Female Hypoactive Sexual Desire Disorder - Products under Development by Companies 12
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development 13
Apricus Biosciences, Inc. 13
Palatin Technologies, Inc. 14
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
(bupropion hydrochloride + trazodone hydrochloride) - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
(buspirone hydrochloride + testosterone) - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
(sildenafil citrate + testosterone) - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
alprostadil - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
bremelanotide - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
flibanserin - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Female Hypoactive Sexual Desire Disorder - Recent Pipeline Updates 36
Female Hypoactive Sexual Desire Disorder - Dormant Projects 44
Female Hypoactive Sexual Desire Disorder - Product Development Milestones 45
Featured News and Press Releases 45
Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD 45
Feb 20, 2012: S1 Pharma Submits IND Application For SIP-104 For Treatment Of Hypoactive Sexual Desire Disorder 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2015 7
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences, Inc., H1 2015 13
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies, Inc., H1 2015 14
Assessment by Monotherapy Products, H1 2015 15
Assessment by Combination Products, H1 2015 16
Number of Products by Stage and Target, H1 2015 18
Number of Products by Stage and Mechanism of Action, H1 2015 20
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Female Hypoactive Sexual Desire Disorder Therapeutics - Recent Pipeline Updates, H1 2015 36
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2015 44

List of Figures

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2015 7
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 15
Number of Products by Top 10 Targets, H1 2015 17
Number of Products by Stage and Top 10 Targets, H1 2015 18
Number of Products by Top 10 Mechanism of Actions, H1 2015 19
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Top 10 Routes of Administration, H1 2015 21
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22
Number of Products by Top 10 Molecule Types, H1 2015 23
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.